Summary
Introduction
Regulation of receptor tyrosine kinases (RTK) by SOCS proteins is much less understood.
In vivo interaction between SOCS proteins and RTK has been previously reported. SOCS1 binds to KIT, FLT3 (29) and FMS (30) . SOCS2 binds to the insulin-like growth factor (IGF) receptor (31) . SOCS1 and SOCS3 bind to EGFR and may downregulate activation of STATs by EGFR (32) . SOCS3 interacts with insuline receptor (IR) (33) . More recently SOCS1 and SOCS6 have also been shown to associate with and inhibit IR downstream signaling events, such as the activation of ERK1/2, AKT, and IRS-1 when expressed in hepatoma cells (34) .
Binding of Stem Cell Factor (SCF) to KIT RTK activates multiple signal transduction components leading to activation of all three MAP kinases pathways, phosphatidylinositol-3 kinase (PI-3K), and STAT1, 3 and 5. We have previously identified SOCS1 protein as downstream component of the KIT receptor signaling pathway (29) . We have demonstrated that SOCS1 bound to KIT via its SH2 domain. Constitutive expression of SOCS1 strongly suppressed the proliferative signals transduced by KIT without suppression of KIT catalytic activity. Neither SOCS1 docking site or the mechanism of SOCS1 inhibition could be determine in these studies. We showed however that SOCS1 not only interacted with KIT and JAK kinases, but also interacted with SH3-domain containing proteins, other receptor tyrosine kinases, and with VAV proteins.
Here, we have screened the putative interactions of SOCS proteins with the KIT receptor in response to SCF stimulation. Our findings reveal that SOCS6 protein interacts with KIT following SCF-stimulated tyrosine phosphorylation. The SH2 domain of SOCS6 binds directly to tyrosine 567 in KIT juxtamembrane domain. To determine the functional consequences of this interaction, we have studied the effect of SOCS6 ectopic expression on the cell proliferation and migration induced by SCF, and investigated which signaling pathways are regulated by SOCS6. manufactured instructions (Cell Signaling). Anti-HA antibody 12CA5 was from hybridoma culture supernatant. Protein A-horse radish peroxidase (HRP) (ICN Biomedicals), goat antimouse IgG-HRP (Jackson Immunoresearch Laboratories) and anti rabbit IgG-HRP (Cell Signaling Technology) were used as secondary antibodies for western blots. Recombinant EGF was obtained from Invitrogen, Phorbol 12-myristate 13-acetate (PMA) from Sigma and anisomycin from Calbiochem.
Transfection procedure
Transfection of COS-7 cells was carried out in 60 mm plates. Cells were transfected with FuGEN6 (Roche Applied Science) as recommended by the manufacturer's instructions with 1µg of expression vector. Cells were serum-starved overnight 24h after transfection in DMEM with 0.5% FBS, and then stimulated for 5 min with 250ng/ml of mSCF.
Immunoprecipitation and Immunoblotting
Stimulated cells were washed in ice-cold phosphate-buffered saline (PBS) prior to lysis, pelleted and lysed in HNTG (50mM HEPES pH7, 50mM NaF, 1mM EGTA, 150mM NaCl, 1% Triton X-100, 10% glycerol, 1.5mM MgCl 2 ) containing protease inhibitor cocktail (Roche Applied Science) and 100µM Na 3 VO 4 . Clarified whole-cell lysates were mixed for 18h with 2µg of antibodies and a bed volume of 10µl of protein A or protein G sepharose (Amersham) for immunoprecipitation. The immunoprecipitates were washed three times with HNTG buffer and dissolved in SDS sample buffer. Following sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) proteins were transfered to polyvinylidene difluoride membranes (Immobilon-P, Millipore). Membranes were saturated with 5% bovine serum albumin (BSA; Sigma) and probed with different antibodies as specified in the text and figure legends. Blots were revealed using HRP-conjugated secondary antibodies and an ECL detection kit (Amersham).
Yeast two-hybrid system
The entire cytoplasmic domains of wild type murine KIT, KIT-JM or KIT-KI mutants (nucleotides 1646-2988) were fused to LexA DNA binding domain in the yeast expression vector pBTM116. SOCS6 cDNA coding for SH2 and C-terminal domains (amino acids 310-533), SOCS6 SH2 domain alone (amino acids 310-479), and SOCS1 full length cDNA were cloned in the vector pACT2 using the Gateway system (Invitrogen). The vectors pLexA-lamin and pACT2 were used as controls for each yeast two-hybrid experiment.
GST pull-down experiments
The glutathione S-transferase (GST)-SOCS6 construct in pDEST15 vector expressing SOCS6 amino acids 310-533 was introduced in the E. coli Rosetta (DE3) pLacI strain (Novagen).
Bacterial cultures grown to log phase were induced with 0.1 mM isopropyl-b-Dgalactopyranoside (IPTG, Invitrogen) for 4h at 30°C. Bacteria were then lysed in HNTG and the GST fusion proteins were purified on glutathione-Sepharose beads (Amersham). Lysates from non stimulated and SCF-stimulated Ba/F3-KIT cells were incubated overnight at 4°C with 5mg of the GST fusion construct or with 5mg of GST-bCatenin control immobilized on gluthatione-Sepharose beads. The beads were washed three times in HNTG and bound fractions were separated by SDS-PAGE and transferred to PVDF membranes. Bound KIT protein was visualised by Western blotting using the 4G10 antibody.
Peptide binding assay
Forty four 15-mer peptides corresponding to the 22 tyrosine motifs of KIT intracellular domain either phosphorylated or not were synthesized on aminopegylated cellulose membranes as described (36) . The membranes were saturated with 10% FBS in TBST buffer (100 mM Tris-HCl pH7.5, 150mM NaCl, 1% Tween 20) for one hour at room temperature. It was then probed overnight at 4°c with [g 
Infection of cells with retroviral vectors
Stable populations of GP+E-86 cells producing MIEV or MIEV-SOCS6 retroviruses were obtained as follow. Phoenix A cells were transfected using FuGEN6 reagent with pMIEVSOCS6 or empty pMIEV. In the next two days, filtered retroviral culture supernatants were used to infect GP+E-86 cells. GP+E-86 populations were then sorted for GFP expression. Infections of Ba/F3 or EML cells were done by co-culture in 100 mm plates using with the target cell culture media and 4 ng/ml of polybrene (Sigma). Non-adherent cells were collected 48h later and sorted for expression of GFP using a cell sorter. Infected R4 MEFs were obtained through similar procedures but with filtered retroviral culture supernatant instead of co-culture.
Cell proliferation assay
A total of 5000 cells per well were plated in triplicate into 96-well plates in 100µL of RPMI medium with 10% FBS and 250 ng/mL of SCF. Cells were incubated for 24h at 37°c and pulsed for 6h with 0.5 µCi of methyl- 
In vitro two-chamber migration assay
Chemotaxis was assayed by a modification of the Boyden chamber assay. 
Results

SOCS6 protein associates with KIT receptor in response to SCF
We earlier reported that SOCS1 physically associated with KIT receptor through its SH2 domain in response to KIT-ligand (SCF) induced activation (29) . To determine whether the other SOCS proteins interacted with KIT, we transiently expressed FLAG-tagged SOCS proteins and KIT in COS-7 cells. Transfected cells were serum-starved overnight prior to stimulation with SCF for 5 min. SCF induced strong association of SOCS6 with KIT ( Fig.1) and a weak association of SOCS4 and SOCS5 with KIT (data not shown). By contrast, CIS bound to KIT constituvely, while SOCS2 and SOCS3 did not interact (data not shown).
Transcripts encoding CIS, SOCS1, SOCS2 and SOCS3 are upregulated following cytokine signaling (1-3). As shown Figure 2A , expression of socs6 gene is induced after 1 hour of SCF stimulation in primary cultures of bone-marrow-derived mast cells. Additionally, socs6
mRNA is present in cells that express KIT, including in the cell lines UT-7, TF1, MO7e cells and in ES cells (Fig. 2B ). These data indicate that socs6 is expressed in KIT positive cells and that KIT signaling induces socs6 mRNA expression.
We set out to analyse the interaction of SOCS6 with KIT. As shown We then studied the kinetics of SOCS6 / KIT interaction. As shown in Figure 3 
SOCS6 SH2 domain interacts with KIT phosphorylated at position Y567
The fact that the KIT/SOCS6 association required the phosphorylation of KIT suggested that the interaction involved SOCS6 SH2 domain and a phosphotyrosine residue in KIT. Using the yeast two-hybrid system, we recapitulated the KIT/SOCS6 interaction and found that SOCS6 SH2 domain alone was sufficient to interact with KIT intracellular domain, although the interaction was weaker than with longer SOCS6 constructs (Fig.4A ).
KIT contains 22 tyrosine residues in the cytoplasmic domain, 11 of which lie outside the kinase domain ( indicating that Y567 and Y569 were necessary for the interaction (not shown). To further investigate the requirement for Y567 and Y569, GST pull-down experiments were done using cell lysates from Ba/F3-KIT, Ba/F3-KITY567F and Ba/F3-KITY569F cell lines. GST-SOCS6
or GST-bcatenin control fusion proteins were immobilized on glutathione-sepharose beads and were mixed with SCF-stimulated cell lysates. The interaction with activated KIT was revealed using the 4G10 antibody. GST-SOCS6, but not GST-bcatenin, associated with KIT WT following SCF stimulation ( Fig. 5B lane 2) . Mutation of either Y567 or Y569 abolished the interaction indicating that both tyrosine residues were indeed required for SOCS6 binding.
Finally, to determine both whether the interaction is direct or indirect and which of the two phospho-tyrosine residues is targeted by SOCS6 SH2 domain, we screened 44 peptides corresponding to all 22 motifs with Y residues in KIT intracellular domain either phosphorylated or not. The peptides were immobilized on a membrane and subjected to far western blotting using radiolabelled GST-SOCS6 protein as a probe. Phospho-peptide INGNNpY 567 VY 569 IDPTQLP containing phosphorylated Y567 and non phosphorylated Y569
was the major peptide recognized by GST-SOCS6 (Fig. 6) . Interestingly, the same peptide sequence phosphorylated at both 567 and 569 positions did not interact with SOCS6. We concluded that SOCS6 interacts directly with KIT and that the binding site is the amino-acid sequence surrounding phosphorylated Y567.
SOCS6 negatively regulates KIT receptor proliferation signal, but not SCF-induced chemotaxis
It is hypothesized that SOCS proteins are negative regulators of cytokines. We first tested the negative potential of SOCS6 on KIT-dependent cellular proliferation. Ba/F3-KIT cells were infected by coculture with retrovirus-producing GP+E-86 cells stably expressing either the empty retroviral vector pMIEV or pMIEV-SOCS6. As a positive control, we used GP+E-86 cells stably expressing pMIEV-SOCS1, since we have previously shown that SOCS1
abolished KIT-dependent mitogenic signals (29) . An IRES sequence in pMIEV-SOCS6 and pMIEV-SOCS1 constructs allows transcription of a single mRNA encoding for both enhanced green fluorescent protein (EGFP) proteins (Fig.7A) and SOCS (Fig.7B ). Infected cells were isolated on the basis of EGFP expression by flow-cytometry cell sorting (Fig.7A ). In these and the following experiments, the expression of KIT was not affected by SOCS6 ectopic expression (Fig.7A) . A thymidine incorporation assay was carried out immediately after cell sorting. We repeatedly observed that SOCS6 ectopic expression led to 40% decrease of cell proliferation compared to control MIEV cells in response to SCF (Fig.7C) . We also consistently observed a moderate decreased of cell proliferation in response to IL-3. To control that SOCS6 is not general inhibitor of cell proliferation, we tested the proliferation of Ba/F3-EGFR cells. Figure 7D shows that cell proliferation of Ba/F3-EGFR cells is not inhibited when SOCS6 protein is expressed. rather we consistently observed that SOCS6 increased cell proliferation. The inhibition of SCF-mediated cell proliferation was confirmed using another cell line, EML-C1 (50% decrease of cell proliferation), which expresses endogenous KIT and is dependent on SCF for cell proliferation (Fig. 7E ).
SCF induces chemotaxis of hematopoietic cells (37) . We have examined the effect of ectopic expression SOCS6 on cell migration using an in vitro 2-chamber assay. The dose response to SCF chemotactic property was assessed for Ba/F3-KIT cells. The optimal chemotactic response was obtained at 100 ng/mL SCF in the lower chamber (not shown). We have also evaluated the kinetics of migration in response to SCF within a range from 30 min to 4 hours.
The best percentage of cell that migrate in the presence of SCF over the non-specific migration (in the absence of SCF) was obtained after 1 hour of migration. Ba/F3-KIT cells expressing SOCS6 showed identical migration induced by SCF to control cells (Fig.8) . We concluded that SOCS6 partially inhibited SCF-induced cell proliferation but not SCF-induced chemotaxis.
ERK and p38 MAPK activation downstream of KIT but not AKT nor STATs are downregulated by SOCS6
We next explored how SOCS6 protein affected SCF-mediated signal transduction, thereby leading to inhibition of cell proliferation. Ba/F3-KIT cells expressing SOCS6 protein or the empty vector were stimulated or not with SCF for 5 min, then activation of ERK1/2 and p38
MAPK was examined by western blotting using phospho-specific antibodies. SCF-mediated activation of ERK1/2 and p38 are reduced in Ba/F3-KIT cells expressing SOCS6, by 25% and 50% respectively (Fig. 9A) . We preferentially observed the phosphorylation of ERK2 over ERK1 in response to KIT activation in these and in the following experiments. By contrast phosphorylation of STAT5 following KIT activation was not modified (Fig. 9B) . We next analysed these pathways in other cell lines. COS-7 cells were transfected with FLAG-tagged SOCS6 and KIT, SCF-mediated activation of ERK1/2 and p38 MAPK were reduced by 50%
in the presence of SOCS6 (Fig. 10A lanes 4 and 5) . These results were confirmed in mouse embryonic fibroblasts (MEFs) stably expressing KIT and SOCS6 protein (Fig. 10B) . Again, ectopic expression of SOCS6 inhibited SCF-mediated activation of p38 and ERK1/2 (80% and 75% reduction respectively), but not AKT activation (Fig 10C) . These results indicate that SOCS6 reduced the activation of MAP-kinases following activation of KIT.
We next investigated whether SOCS6 inhibited ERK1/2 and p38 activation by other stimuli.
We first tested the stimulation of MEFs with EGF. Figure 11A shows that SOCS6 protein did not downregulate the ERK1/2 and p38 MAPK activation by EGF. We also examined the activation of ERK1/2 and p38 proteins by PMA and anisomycin respectively. The expression of SOCS6 in MEFs did not impair the activation of ERK1/2 and p38 MPAK induced by PMA (Fig. 11B) and anisomycin (Fig. 11C) treatments. We concluded that SOCS6 is not an inhibitor of the MAP kinases pathway. Rather, SOCS6 protein specifically inhibits an early event in KIT signaling, that is upstream of ERK1/2 and p38 activation.
Discussion
The present study was initiated to investigate the implication of members of the SOCS family in the regulation of KIT receptor signaling. We report that SOCS6 directly interacts with KIT and may downmodulate signaling pathways initiated in KIT juxtamembrane domain resulting in decreased cell proliferation.
While multiple studies have been published on SOCS family members CIS, SOCS1, 2 and 3, very little is known about the larger members SOCS4-7. We have previously identified SOCS1 as a KIT binding protein in a Yeast two-hybrid screen. We then tested whether the other members of the family were KIT interactors. We found that SOCS4 and SOCS5 weakly interacted while CIS and SOCS6 stably interacted with KIT. 
SOCS6 binds a multifunction docking site
Modulation of KIT signaling by SOCS
We had previously shown that SOCS1 bound to KIT and that SOCS1 ectopic expression inhibited KIT ligand dependent cell proliferation (29) . Since SOCS proteins -CIS, SOCS2
and SOCS3-have also been implicated in the negative regulation of cytokines or growth factor signaling, we tested whether SOCS6 modulated KIT mediated cell proliferation and KIT mediated chemotaxis. SOCS6 partially inhibited cell proliferation while inhibition by SOCS1 was total. In our experiments, SOCS1 was consistently expressed at higher levels than SOCS6, which may account for this difference (Fig 7B) . SOCS6 low expression level compared to smaller SOCS proteins was previously noticed by others (42) . Interestingly, SOCS6 did not impair KIT-ligand mediated chemotaxis indicating that some specific signaling pathways were inhibited while others were unaffected.
The MAPK pathways ERK1/2 and p38 are in part activated through Y567 in the juxtamembrane membrane region of KIT (37) . SRC and SHP2, two putative Y567 interactors, are likely to be upstream activators of MAPKs in KIT signaling (37, 43) . We observed that SOCS6 partially inhibited ERK and p38 both in fibroblasts and in the Ba/F3 hematopoietic cell line, but did not affect AKT or STAT5 phosphorylation.
Ueda et al (2002) reported that Y567 in KIT is implicated in the activation of SRC family kinases and that the Y567F mutant showed reduction of MEK1/2 and p38 phosphorylation.
The reduction they observed with KIT Y567F is very similar to the partial reduction we detected following ectopic expression of SOCS6. These independent observations support our mapping and ectopic expression data. SOCS6 may bind to Y567 and mask this multifunction docking site, thus mimicking the Y567F mutation.
Activation of ERK and p38 pathways through EGFR, PMA or anisomycin stimulation were not inhibited by SOCS6 indicating that the inhibition takes place in the initial stages of KIT activation. Two SOCS proteins are thought to downregulate signaling through competition for binding sites on membrane receptors. First, it has been suggested that CIS inhibits STAT5
phosphorylation following GH or EPO activation by binding to STAT5 binding sites on the respective cytokine receptors (6) . Second, the SH2 domains of SOCS3 and SHP2 have similar binding specificities in vitro (44) . Other studies showed that SOCS3 and SHP2 share the same docking sites on gp130 (22, 23) , EPOR (21) and Leptin receptor (24) . In a similar way, SOCS6 might prevent the recruitment of the SH2 domain-containing proteins such as SRC and SHP2 to the receptor and thereby reduce the activation of downstream pathways (ERK and p38).
Despite the generation of SOCS6 knock-out mice (26) , the biological action of SOCS6 remains largely unknown. hematopoiesis in mice deficient for SOCS6 seems normal. Indeed SOCS6-/-mice do not have obvious phenotypes other than a 10% weight deficit. One possible explanation for the lack of phenotype could be that SOCS7 and SOCS6 have overlapping functions. SOCS7 is about 55% identical to SOCS6 within the SH2 and SOCS box domains.
The binding specificity of both SH2 domains is very similar as determined in peptide binding assays (26) . Furthermore, both SH2 domains were shown to co-precipitate with identical phosphorylated proteins including IRS-2, IRS-4, p85a, p85b and tubulin (26) . The SH2 domain of SOCS7 can interact with KIT (our unpublished data) suggesting that SOCS7 could also bind Y567 in KIT and be involved in the regulation of KIT signaling. The generation of double deficient mice for both SOCS6 and SOCS7 should shed light on the presumptive overlapping functions of these two proteins.
The Insulin receptor (IR) is the only other receptor that has been shown to interact with SOCS6 (34) . In that case, phosphorylation of ERK1/2, AKT and IRS-1 were inhibited by 
